Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 19036157 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Stratford AL, et al. (2008) Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10, R99 19036157
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human) ▲
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
gefitinib decrease

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
gefitinib decrease

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
gefitinib decrease

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
gefitinib decrease

S380-p - p90RSK (human) ▲
Orthologous residues
p90RSK (human): S380‑p, p90RSK iso3 (human): S389‑p, p90RSK (mouse): S369‑p, p90RSK iso3 (mouse): ‑, p90RSK (rat): S380‑p, p90RSK (chicken): S398‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase

S102-p - YB-1 (human) ▲
Orthologous residues
YB‑1 (human): S102‑p, YB‑1 (mouse): S100‑p, YB‑1 (rat): S100‑p
Characterization
 Methods used to characterize site in vivo:  immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  breast cancer
 Relevant cell lines - cell types - tissues:  HCC1937 (breast cell), MDA-MB231 (breast cell), MDA-MB468 (breast cell), SUM159
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE RSK2 (human)
KINASE p90RSK (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE RSK2 (human) pharmacological inhibitor of upstream enzyme, activation of upstream enzyme, genetic knockout/knockin of upstream enzyme, transfection of constitutively active enzyme, siRNA inhibition of enzyme
KINASE p90RSK (human) pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, co-immunoprecipitation, transfection of constitutively active enzyme, siRNA inhibition of enzyme, transfection of inactive enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
serum increase
PD98059 serum inhibit treatment-induced increase
EGF increase
PD98059 EGF inhibit treatment-induced increase
phorbol ester increase
PD98059 phorbol ester inhibit treatment-induced increase
gefitinib decrease
PD98059 decrease
SL0101 decrease
Downstream Regulation
 Effect of modification (function):  activation
 Effect of modification (process):  transcription, altered
Associated Diseases
Diseases: Alterations: Comments:
breast cancer increased


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.